(-0.07%) 5 474.75 points
(-0.11%) 38 776 points
(-0.03%) 19 915 points
(0.20%) $80.49
(1.22%) $2.82
(0.24%) $2 334.70
(-0.11%) $29.36
(-0.21%) $968.90
(0.01%) $0.932
(-0.16%) $10.64
(0.06%) $0.788
(-1.87%) $86.79
2 days till quarter result
(tns 2024-06-20)
Expected move: +/- 11.02%
Live Chart Being Loaded With Signals
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation...
Stats | |
---|---|
Šios dienos apimtis | 359 537 |
Vidutinė apimtis | 375 977 |
Rinkos kapitalizacija | 102.59M |
EPS | $-0.360 ( Q1 | 2024-05-06 ) |
Kita pelno data | ( $-0.330 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.120 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00200 (0.11%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-31 | Certel Kaan | Buy | 220 000 | Stock Option (Right to Buy) |
2024-05-28 | Certel Kaan | Buy | 0 | |
2024-05-31 | Chan Barbara Y | Sell | 0 | Common Stock |
2024-05-31 | Chan Barbara Y | Sell | 50 000 | Stock Option (Right to Buy) |
2024-05-31 | Chan Barbara Y | Sell | 20 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
80.62 |
Last 92 transactions |
Buy: 34 649 434 | Sell: 13 609 680 |
Tūris Koreliacija
Omega Therapeutics, Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
ISSC | 0.87 |
DLHC | 0.865 |
POAI | 0.861 |
EZGO | 0.856 |
MPAA | 0.851 |
RPTX | 0.847 |
MBIO | 0.846 |
EYEN | 0.846 |
HDSN | 0.841 |
RCKT | 0.84 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
CENX | -0.855 |
GRIN | -0.841 |
GERN | -0.837 |
SMTC | -0.834 |
PPTA | -0.833 |
NN | -0.833 |
CURI | -0.832 |
GALT | -0.83 |
LABP | -0.825 |
STAA | -0.824 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Omega Therapeutics, Inc. Koreliacija - Valiuta/Žaliavos
Omega Therapeutics, Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $3.09M |
Bruto pelnas: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2023 |
Pajamos: | $3.09M |
Bruto pelnas: | $-3.68M (-118.84 %) |
EPS: | $-1.800 |
FY | 2022 |
Pajamos: | $2.07M |
Bruto pelnas: | $-3.12M (-150.36 %) |
EPS: | $-2.14 |
FY | 2021 |
Pajamos: | $144 000 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Omega Therapeutics, Inc.
Omega Therapeutics, Inc. operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer. It is also developing OTX-2002 to down-regulate c-Myc, an oncogene. The company was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.